title: Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood.
abstract: BACKGROUND
  Children with Prader-Willi syndrome (PWS) who receive GH treatment have improved growth and body composition; however, data are lacking for adults when treatment is discontinued after completion of growth.
  
  
  OBJECTIVE
  Our aim was to compare body composition and metabolic status in adults with PWS according to GH treatment in childhood and adolescence.
  
  
  METHODS
  64 adults (mean age: 25.4 years) with a genetic diagnosis of PWS were evaluated: 20 received GH in childhood (T), which had been discontinued at the time of this study, and 44 did not receive GH (C). Mean duration of treatment in the T group was 4.4 ± 2.7 years, age at baseline was 11.8 ± 2.7 years, mean time between the end of treatment and the current evaluation was 7.0 ± 4.4 years.
  
  
  METHODS
  Dual-energy X-ray absorptiometry was used to assess body composition and fasting biological analyses evaluated metabolic status. RESULTS (MEAN ± SD): Body mass index and percentage of fat mass were significantly lower in the T group (32.4 ± 10.3 vs 41.2 ± 11.1 kg/m(2), P = 0.05 and 44.0 ± 9.6 vs 50.1 ± 7.2%, P = 0.02, respectively). Insulinemia and HOMA-IR in non-diabetic subjects were significantly lower in the T group (5.8 ± 5.9 vs 13.9 ± 11.6 μUI/ml, P = 0.03, and 1.6 ± 1.3 vs 2.7 ± 2.1, P = 0.04, respectively). Non-diabetic and diabetic subjects from the T group had a significantly lower HbA1c. Lipid profiles were similar between groups.
  
  
  CONCLUSIONS
  GH treatment in childhood and adolescence is associated with significantly decreased body mass index and improved body composition and metabolic status in adults with PWS at several years after discontinuing treatment.
authors.affiliation: Service de nutrition, Hôpital Pitié Salpêtrière (AP-HP), 47-83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France. muriel.coupaye@lmr.aphp.fr
authors.forename: Muriel
authors.initials: M
authors.lastname: Coupaye
authors.forename: Françoise
authors.initials: F
authors.lastname: Lorenzini
authors.forename: Célia
authors.initials: C
authors.lastname: Lloret-Linares
authors.forename: Catherine
authors.initials: C
authors.lastname: Molinas
authors.forename: Graziella
authors.initials: G
authors.lastname: Pinto
authors.forename: Gwenaëlle
authors.initials: G
authors.lastname: Diene
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Mimoun
authors.forename: Geneviève
authors.initials: G
authors.lastname: Demeer
authors.forename: Florence
authors.initials: F
authors.lastname: Labrousse
authors.forename: Joseba
authors.initials: J
authors.lastname: Jauregi
authors.forename: Virginie
authors.initials: V
authors.lastname: Laurier
authors.forename: Arnaud
authors.initials: A
authors.lastname: Basdevant
authors.forename: Michel
authors.initials: M
authors.lastname: Polak
authors.forename: Denise
authors.initials: D
authors.lastname: Thuilleaux
authors.forename: Maïthé
authors.initials: M
authors.lastname: Tauber
authors.forename: Christine
authors.initials: C
authors.lastname: Poitou
mesh_terms: D000293:Adolescent; D000328:Adult; D001481:Basal Metabolism / Q000187:drug effects* / Q000502:physiology; D001823:Body Composition / Q000187:drug effects* / Q000502:physiology; D015992:Body Mass Index; D002648:Child; D005260:Female; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011218:Prader-Willi Syndrome / Q000188:drug therapy* / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D019382:Human Growth Hormone